FDA Withdraws Emergency Use Authorization For AstraZeneca’s COVID-19 Antibody Cocktail Tixagevimab/Cilgavimab
Reuters (1/26) reports the FDA “has withdrawn emergency-use authorization for AstraZeneca’s COVID-19 antibody cocktail” tixagevimab/cilgavimab (Evusheld) “as the treatment is not expected to neutralize the currently dominant XBB.1.5 subvariant of Omicron.” The company “said it was informed that the agency will decide about reinstating authorization of Evusheld if the prevalence of resistant variants in the […]
